Moderna COVID vaccine sales forecast unchanged even as COVAX program cuts orders
Reuters
Published Aug 03, 2022 07:11AM ET
Updated Aug 03, 2022 01:53PM ET
By Michael Erman and Manas Mishra
(Reuters) - Moderna (NASDAQ:MRNA) Inc on Wednesday maintained its full-year COVID-19 vaccine sales forecast of $21 billion as canceled orders from low- and middle-income nations through the COVAX program offset gains from new booster dose orders.
Moderna shares jumped nearly 17% in morning trading after the company also announced a $3 billion share buyback plan.
Moderna has begun producing a redesigned booster shot targeting both the original coronavirus as well as the BA.4 and BA.5 Omicron subvariants.
It signed a $1.74 billion deal with the U.S. government last week for 66 million doses to be available this fall and winter, if cleared by health regulators.
Despite the contract, Moderna kept its sales forecast unchanged as doses earmarked for the COVAX vaccine sharing program remain unallocated due to low demand.
"It's because of COVAX," Chief Executive Stephane Bancel said in an interview. "COVAX does not want the doses that they have ordered."
Moderna and rival Pfizer Inc (NYSE:PFE) have been banking on recurring booster doses, including an Omicron-tailored version, to garner more vaccine contracts with higher-income countries.
"We do believe the majority of the market demand is captured in this $21 billion. That being said, we continue to work with countries around the world on potential additional orders," said Chief Commercial Officer Arpa Garay.
Other countries are considering an earlier version of the booster shot designed to target the BA.1 Omicron variant that led to a record surge in infections last winter, rather than the currently dominant BA.5 or related BA.4.
Those shots had been in production already and would be available sooner, Bancel said.
"There are plenty of countries around the world that would rather start early - as early as August," he added.
"Some of those countries have said they would rather start with the BA.1 now and then go to BA.4 later versus just waiting and hoping."
Some countries could authorize the retooled BA.1 boosters within the next few weeks, the CEO said.
Get The News You Want
Moderna reported $4.5 billion in COVID vaccine sales in the second quarter. It took a $499 million charge related to vaccines that have expired.
Moderna shares were up 16.7% at $187.60 but are off about 30% for the year to date.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.